About Autolus

Autolus is a biopharmaceutical company developing next-generation, programmed T-cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T-cell programming technologies, Autolus is engineering precisely targeted, controlled, and highly active T-cell therapies that are designed to better recognize target cells, break down their defense mechanisms, and eliminate these cells. Autolus has an FDA-approved product, obecabtagene autoleucel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors, and autoimmune diseases.

OBECABTAGENE AUTOLEUCEL IS APPROVED FOR USE ONLY IN THE US.

AUTOLUS IS FOUNDED ON ADVANCED CELL PROGRAMMING TECHNOLOGY

2014

- Autolus is founded by Dr Martin Pule and spun out from University College London

2016-2017

- Early clinical trials started in acute lymphoblastic leukemia (ALL), multiple myeloma, non-Hodgkin lymphoma, and neuroblastoma
- Collaboration with CGT Catapult for manufacturing facility

2018-2019

- Successful initial public offering
- Office opened in Maryland, US

2020-2021

- Pivotal clinical trial FELIX started in adult ALL
- Strategic collaboration with Blackstone Life Sciences to develop obecabtagene autoleucel

2022-2023

- FELIX pivotal trial interim analysis completed
- Good Manufacturing Practices commercial facility validation completed
- Technology licensing agreements with Bristol Myers Squibb®, Moderna®, and Cabaletta Bio®

2024

- Obecabtagene autoleucel FDA approval in November
- Strategic multiplatform R&D collaboration with BioNTech

Since 2014 we have undergone rapid growth, systematically adding the capabilities to manufacture, develop, and commercialize our programmed T-cell investigational product candidates.

MODULAR INNOVATION

Broad suite of proprietary and modular T-cell programming technologies

EXTENSIVE PIPELINE

Multiple candidates in development for the treatment of hematologic cancers and solid tumor malignancies as well as other serious diseases

RELIABLE MANUFACTURING

Robust manufacturing process and facility with sufficient capacity for global demand in ALL

Our team is participating in the American Society for Transplantation and Cellular Therapy 80/20 initiative.

FDA=US Food and Drug Administration.